# siRNA Drugs: Mechanism, Examples, and Clinical Applications ## Key Takeaways - siRNA drugs leverage the endogenous RNA interference (RNAi) pathway to achieve gene silencing by targeting and degrading disease-causing messenger RNA (mRNA) transcripts, thereby preventing protein synthesis. This mechanism allows for the targeting of previously "undruggable" genes. - The therapeutic efficacy of siRNA drugs relies on chemically modified synthetic siRNAs, typically 19–21 base pairs, designed for optimal guide strand loading into the RNA-induced silencing complex (RISC) and subsequent mRNA cleavage by Argonaute 2 (Ago2). - Delivery of siRNA drugs to target cells is a critical challenge, with lipid nanoparticles (LNPs) and N-acetylgalactosamine (GalNAc) conjugates being the most advanced strategies, enabling efficient hepatic uptake via endocytosis and subsequent endosomal escape. - Six siRNA drugs are currently approved, primarily targeting liver-expressed genes for rare genetic disorders and hypercholesterolemia, including patisiran (TTR target), givosiran (ALAS1 target), lumasiran (HAO1 target), inclisiran (PCSK9 target), vutrisiran (TTR target), and nedosiran (LDHA target). - While offering high specificity and potency due to the catalytic nature of RISC, limitations include challenges in extrahepatic delivery, potential off-target effects mediated by the siRNA seed region, and immune stimulation from certain RNA motifs, necessitating careful chemical modification and formulation. --- ## Introduction to siRNA Drugs [Small interfering RNA](/knowledge/molecular-biology/small-interfering-rna) (siRNA) drugs are a class of therapeutic agents that exploit the endogenous RNA interference (RNAi) pathway to silence disease-causing genes at the messenger RNA (mRNA) level. Unlike traditional small molecule drugs that inhibit protein function, siRNA drugs act upstream by degrading the mRNA transcript before it can be translated into protein. This fundamental difference allows siRNA therapeutics to target genes that were previously considered "undruggable" by conventional pharmacology. ### What is RNA interference? RNA interference is a highly conserved biological process present in eukaryotic cells that regulates gene expression post-transcriptionally. The pathway was first characterized in *Caenorhabditis elegans* by Fire and Mello in 1998, work that earned them the Nobel Prize in Physiology or Medicine in 2006. In nature, RNAi serves as a defense mechanism against viral infection and [transposable elements](/knowledge/molecular-biology/transposable-element), while also participating in endogenous gene regulation. The RNAi pathway begins when long double-stranded RNA (dsRNA) molecules are processed by the RNase III enzyme Dicer into shorter fragments of 21–23 nucleotides. These fragments, the siRNAs, possess characteristic 2-nucleotide overhangs at their 3′ ends and phosphorylated 5′ ends. One strand of the siRNA duplex—the guide strand—is loaded into the RNA-induced silencing complex (RISC), while the passenger strand is degraded. The guide strand then directs RISC to complementary mRNA sequences, resulting in endonucleolytic cleavage and subsequent degradation of the target transcript. ### From gene silencing to therapeutic agents The therapeutic potential of RNAi was recognized almost immediately after its discovery. The concept is elegantly simple: if a disease is caused by overexpression of a particular gene or by a dominant mutant allele, delivering an siRNA complementary to that gene's mRNA should reduce its protein product. However, translating this concept into viable drugs took over two decades due to formidable challenges in stability, delivery, and specificity. The first siRNA drug, patisiran, received FDA approval in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis. Since then, five additional siRNA drugs have entered the clinic, with dozens more in various stages of clinical development. These drugs represent a paradigm shift in medicine—they are the first class of therapeutics that intentionally harness a natural gene-silencing mechanism rather than inhibiting protein function directly. ## Mechanism of Action of siRNA Drugs The mechanism of action of siRNA drugs mirrors the endogenous RNAi pathway but with several critical adaptations for therapeutic use. Understanding this mechanism at the molecular level is essential for appreciating both the power and the limitations of this drug class. ### siRNA structure and design Therapeutic siRNAs are synthetic double-stranded RNA molecules, typically 19–21 base pairs in length, with two-nucleotide deoxythymidine or deoxyuridine overhangs at the 3′ ends. Each strand contains a 5′ phosphate group, which is essential for RISC loading. The guide strand (also called the antisense strand) is complementary to the target mRNA, while the passenger strand (sense strand) is complementary to the guide strand. Designing an effective siRNA requires careful consideration of several parameters. The target sequence should be unique to the intended gene to minimize off-target effects. Sequence motifs such as GC content (ideally 30–52%), the absence of internal repeats, and the presence of specific nucleotide preferences at positions 1 and 19 influence strand selection and silencing efficiency. Thermodynamic stability of the duplex ends is particularly important: the strand with the less stable 5′ end is preferentially loaded into RISC as the guide strand. Various algorithms have been developed to predict effective siRNA sequences, and these are discussed in detail in resources on [siRNA design](/knowledge/molecular-biology/design-sirna). ### RISC assembly and guide strand selection Once the synthetic siRNA enters the cytoplasm, it must be loaded into the RNA-induced silencing complex. The core component of RISC is an Argonaute (Ago) protein, specifically Ago2 in humans, which possesses the endonucleolytic activity responsible for mRNA cleavage. The loading process is mediated by the [chaperone proteins](/knowledge/molecular-biology/chaperone-protein) Hsp70 and Hsp90, which facilitate the ATP-dependent unwinding of the siRNA duplex. During RISC loading, the siRNA duplex is bound by Ago2, and the passenger strand is cleaved and released. The guide strand remains associated with Ago2, with its 5′ end anchored in a conserved binding pocket and its 3′ end positioned in the PAZ domain. The guide strand is then positioned such that nucleotides 2–8 (the "seed region") are pre-organized in an A-form helical conformation, ready to base-pair with complementary mRNA sequences. This seed region is the primary determinant of target recognition and is also the source of most off-target effects, as complementarity to the seed region alone can mediate translational repression. ### mRNA cleavage and gene silencing Target recognition occurs when the guide strand base-pairs with complementary sequences in the target mRNA, typically in the coding region or 3′ untranslated region. Perfect complementarity between the guide strand and the mRNA—particularly in the central region (nucleotides 10–11 relative to the guide 5′ end)—triggers Ago2-mediated endonucleolytic cleavage. Ago2 cleaves the phosphodiester bond between nucleotides 10 and 11 of the mRNA, generating a 5′ phosphate and a 3′ hydroxyl group. The cleaved mRNA fragments are then rapidly degraded by cellular exonucleases, effectively eliminating the transcript from the cell. Because each RISC complex can catalyze multiple rounds of cleavage, a single siRNA molecule can silence many mRNA transcripts, providing potent and sustained gene knockdown. This catalytic mechanism distinguishes siRNA from [antisense oligonucleotides](/knowledge/molecular-biology/antisense-oligonucleotide) (ASOs), which act stoichiometrically—one ASO molecule inactivates one mRNA molecule. The duration of silencing depends on the rate of cell division (dilution of the siRNA) and the stability of the RISC complex. In non-dividing cells, gene silencing can persist for weeks. This property is exploited therapeutically, as several siRNA drugs require dosing only once every few months. For a comprehensive overview of the silencing process, see the article on [siRNA knockdown](/knowledge/molecular-biology/sirna-knockdown). ## Chemical Modifications and Delivery Strategies Bare, unmodified siRNA molecules are poor drugs. They are rapidly degraded by serum nucleases, have short half-lives in circulation (typically minutes), are rapidly cleared by renal filtration, and do not readily cross cellular membranes due to their size (~13 kDa) and negative charge. Overcoming these barriers requires chemical modification and sophisticated delivery vehicles. ### Stabilizing modifications Chemical modifications to the siRNA backbone and ribose sugars dramatically improve stability without compromising silencing activity. The most common modifications include: - **2′-O-methyl (2′-OMe)**: Addition of a methyl group to the 2′ hydroxyl of the ribose sugar. This modification increases nuclease resistance and reduces immune stimulation. - **2′-methoxyethyl (2′-MOE)**: A bulkier modification that further enhances nuclease resistance and binding affinity. - **2′-fluoro (2′-F)**: Substitution of the 2′ hydroxyl with fluorine increases binding affinity to the target mRNA and confers nuclease resistance. - **Phosphorothioate (PS) linkages**: Replacement of a non-bridging oxygen in the phosphodiester backbone with sulfur. This modification enhances resistance to exonucleases and promotes protein binding, which improves pharmacokinetics. - **Locked nucleic acids (LNA)**: A methylene bridge connecting the 2′ oxygen and 4′ carbon of the ribose, locking the sugar in a C3′-endo conformation. LNAs dramatically increase thermal stability. Modern therapeutic siRNAs, such as those developed by Alnylam Pharmaceuticals, incorporate a combination of these modifications in a pattern that maintains silencing potency while maximizing stability. Typically, 2′-F modifications are placed in the central region of the guide strand, while 2′-OMe modifications are placed at the ends. The passenger strand is often more heavily modified, as it will be degraded anyway. ### Lipid nanoparticles (LNPs) Lipid nanoparticles are the most clinically advanced delivery vehicles for siRNA drugs. LNPs are spherical vesicles composed of ionizable cationic lipids, phospholipids, cholesterol, and polyethylene glycol (PEG)-lipid conjugates. The ionizable lipids are the key component: they are positively charged at low pH (facilitating encapsulation of negatively charged siRNA during formulation) but neutral at physiological pH (reducing toxicity and improving circulation time). The mechanism of LNP-mediated delivery is as follows. After intravenous administration, the LNP circulates in the bloodstream and accumulates in the liver, where fenestrated sinusoidal endothelium allows extravasation into hepatocytes. The LNPs are taken up by cells via endocytosis, and the acidic environment of the endosome triggers protonation of the ionizable lipids. This causes the endosomal membrane to destabilize, leading to the release of siRNA into the cytoplasm—a process called endosomal escape. The efficiency of endosomal escape is a major determinant of LNP efficacy, with only a small fraction of internalized siRNA typically reaching the cytoplasm. Patisiran, the first approved siRNA drug, uses an LNP formulation. However, LNPs require intravenous administration and are associated with infusion-related reactions, which has motivated the development of alternative delivery approaches. For practical guidance on delivering siRNAs in research settings, see the article on [siRNA transfection](/knowledge/molecular-biology/sirna-transfection). ### GalNAc conjugates for liver targeting A major breakthrough in siRNA delivery came with the development of N-acetylgalactosamine (GalNAc) conjugates. GalNAc is a sugar that binds with high affinity to the asialoglycoprotein receptor (ASGPR), which is expressed almost exclusively on hepatocytes. By covalently attaching a triantennary GalNAc cluster to the 3′ end of the passenger strand, siRNA drugs can be delivered specifically to liver cells. The GalNAc-siRNA conjugate is administered subcutaneously, absorbed into the bloodstream, and taken up by hepatocytes via ASGPR-mediated endocytosis. The receptor has an extremely high binding affinity (dissociation constant in the nanomolar range) and is rapidly recycled to the cell surface, allowing efficient uptake. Once inside the endosome, the siRNA must escape to the cytoplasm to engage RISC. The enhanced stability of the chemically modified siRNA allows it to survive the endosomal environment and achieve potent silencing. GalNAc conjugation has several advantages over LNPs: subcutaneous administration (which patients can self-administer), reduced infusion-related reactions, and more predictable pharmacokinetics. Five of the six approved siRNA drugs use GalNAc conjugation. The success of this approach has established the liver as the primary target organ for siRNA therapeutics, as ASGPR expression is largely restricted to hepatocytes. ## Approved siRNA Drugs and Clinical Examples As of 2025, six siRNA drugs have received regulatory approval. All target liver-expressed genes, reflecting the current limitations of delivery technology. Each drug exemplifies a different aspect of siRNA therapeutic development. | Drug | Target Gene | Indication | Delivery | Dosing Frequency | |------|-------------|------------|----------|------------------| | Patisiran | TTR | hATTR amyloidosis | LNP | IV every 3 weeks | | Givosiran | ALAS1 | Acute hepatic porphyria | GalNAc | SC monthly | | Lumasiran | HAO1 | Primary hyperoxaluria type 1 | GalNAc | SC monthly | | Inclisiran | PCSK9 | Hypercholesterolemia | GalNAc | SC twice yearly | | Vutrisiran | TTR | hATTR amyloidosis | GalNAc | SC quarterly | | Nedosiran | LDHA | Primary hyperoxaluria type 1 | GalNAc | SC monthly | ### Patisiran for hereditary ATTR amyloidosis Patisiran (Onpattro) was the first siRNA drug approved by the FDA (2018) and the first RNAi therapeutic of any kind to reach the clinic. It targets the transthyretin (TTR) gene, which encodes a serum protein that transports thyroxine and retinol-binding protein. In hereditary transthyretin-mediated amyloidosis (hATTR), point mutations in TTR cause the protein to misfold and aggregate as amyloid fibrils, leading to progressive peripheral neuropathy and cardiomyopathy. Patisiran is formulated in an LNP and administered intravenously every three weeks. Clinical trials demonstrated that patisiran treatment halted or reversed neuropathy progression in the majority of patients, with significant improvements in quality of life measures. The approval of patisiran validated the entire RNAi therapeutic field and paved the way for subsequent drugs. ### Givosiran for acute hepatic porphyria Givosiran (Givlaari) targets 5-aminolevulinate synthase 1 (ALAS1), the rate-limiting enzyme in heme biosynthesis. In acute hepatic porphyria, partial deficiencies in downstream heme biosynthesis enzymes lead to accumulation of neurotoxic intermediates, particularly aminolevulinic acid (ALA) and porphobilinogen (PBG). These intermediates cause severe abdominal pain, neuropsychiatric symptoms, and potentially life-threatening autonomic instability. By silencing ALAS1, givosiran reduces the production of ALA and PBG at the source. The drug is administered subcutaneously once monthly as a GalNAc conjugate. Clinical trials showed dramatic reductions in porphyria attack rates, with most patients becoming attack-free during treatment. Givosiran represents a particularly elegant application of siRNA therapy because it targets the upstream cause of the disease rather than managing symptoms. ### Lumasiran for primary hyperoxaluria type 1 Lumasiran (Oxlumo) targets hydroxyacid oxidase 1 (HAO1), which encodes glycolate oxidase, an enzyme in the glyoxylate metabolism pathway. Primary hyperoxaluria type 1 is caused by mutations in alanine-glyoxylate aminotransferase (AGXT), leading to excessive oxalate production. Oxalate precipitates as calcium oxalate crystals in the kidneys and urinary tract, causing recurrent kidney stones, nephrocalcinosis, and eventually end-stage renal disease. The therapeutic strategy behind lumasiran is elegant: by silencing HAO1, the enzyme upstream of the metabolic block, the production of glyoxylate (the substrate for oxalate synthesis) is reduced. This "substrate reduction therapy" approach effectively bypasses the defective AGXT enzyme. Lumasiran is administered subcutaneously monthly as a GalNAc conjugate and has shown substantial reductions in urinary oxalate excretion in clinical trials. ### Inclisiran for hypercholesterolemia Inclisiran (Leqvio) targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that promotes the degradation of low-density lipoprotein (LDL) receptors. By silencing PCSK9, inclisiran increases LDL receptor expression on hepatocytes, leading to enhanced clearance of LDL cholesterol from the circulation. Inclisiran is notable for its dosing frequency: a single subcutaneous injection every six months achieves sustained LDL cholesterol reduction of approximately 50%. This infrequent dosing is possible because of the long residence time of the GalNAc-siRNA conjugate in hepatocytes and the slow turnover of the silenced protein. Inclisiran was approved in the EU in 2020 and by the FDA in 2021, and it represents the first siRNA drug for a common chronic disease rather than a rare genetic disorder. ### Vutrisiran for hereditary ATTR amyloidosis Vutrisiran (Amvuttra) is a second-generation TTR-targeting siRNA that uses GalNAc conjugation rather than LNP delivery. It was designed with enhanced chemical modifications to improve metabolic stability and potency, allowing subcutaneous administration once every three months. Vutrisiran demonstrated comparable or superior efficacy to patisiran in clinical trials, with the added convenience of less frequent dosing and self-administration. The development of vutrisiran illustrates the iterative improvement in siRNA drug design: the same target gene can be addressed with progressively better delivery and stability profiles. This "next-generation" approach has become the standard for subsequent siRNA drug development. ## siRNA Drugs in Clinical Trials Beyond the approved drugs, numerous siRNA therapeutics are in clinical development for a wide range of diseases. The expansion of siRNA applications depends on solving delivery challenges for non-liver tissues and on identifying suitable gene targets. ### Cancer therapies Several siRNA drugs are being evaluated for oncology indications. The primary challenge is delivering siRNA to tumor cells, which requires either local administration or active targeting strategies. Approaches under investigation include: - **Intratumoral injection**: Direct injection of siRNA into solid tumors, often formulated with lipid or polymer nanoparticles. This approach has been tested for silencing oncogenes such as KRAS (in pancreatic cancer) and BCL2 (in melanoma). - **Aptamer-siRNA conjugates**: Chimeric molecules where an RNA aptamer that binds a tumor-specific cell surface receptor is covalently linked to an siRNA. For example, an aptamer targeting prostate-specific membrane antigen (PSMA) has been used to deliver siRNAs to prostate cancer cells. - **GalNAc-siRNA for liver cancer**: Hepatocellular carcinoma can be targeted using the same GalNAc delivery platform as approved drugs, with siRNAs directed against oncogenes such as CTNNB1 (β-catenin) or VEGF. A particularly promising approach is the use of siRNA to silence genes involved in chemotherapy resistance. For example, silencing survivin (BIRC5) or multidrug resistance protein 1 (ABCB1) in tumor cells can sensitize them to conventional cytotoxic drugs. ### Antiviral siRNA drugs The COVID-19 pandemic renewed interest in antiviral siRNA therapeutics. In principle, siRNAs can target conserved regions of viral genomes, providing a broad-spectrum antiviral approach that is less susceptible to resistance than small molecule inhibitors. Clinical trials have evaluated siRNA drugs for: - **Hepatitis B virus (HBV)**: Several siRNA drugs targeting HBV transcripts are in clinical trials. These siRNAs silence viral genes including the surface antigen (HBsAg), core protein, and polymerase. The goal is functional cure—sustained loss of HBsAg—which is rarely achieved with current nucleoside analogue therapy. - **Respiratory syncytial virus (RSV)**: An inhaled siRNA targeting the RSV nucleocapsid protein was evaluated in clinical trials but showed limited efficacy, highlighting the challenges of respiratory delivery. - **Hepatitis C virus (HCV)**: Early siRNA candidates targeting HCV were developed, but the advent of highly effective direct-acting antiviral drugs reduced the need for this approach. The challenge for antiviral siRNA drugs is delivery to the site of infection and achieving sufficient intracellular concentrations to inhibit viral replication. For HBV, the liver tropism of GalNAc conjugates provides a natural advantage. ### Rare genetic diseases The most active area of siRNA drug development remains rare genetic diseases, particularly those affecting the liver. The success of the approved drugs has established a clear path to regulatory approval for this indication. Clinical trials are evaluating siRNA drugs for: - **Alpha-1 antitrypsin deficiency**: Silencing the mutant SERPINA1 gene to reduce accumulation of toxic protein aggregates in hepatocytes. - **Primary hyperoxaluria type 2 and 3**: Targeting different enzymes in glyoxylate metabolism. - **Complement-mediated diseases**: Silencing complement component C3 or C5 for conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. - **Hemophilia and bleeding disorders**: Silencing antithrombin (SERPINC1) or tissue factor pathway inhibitor (TFPI) to promote coagulation. - **Amyloidosis beyond TTR**: Targeting serum amyloid A (SAA1) or apolipoprotein A-I (APOA1). The expansion of siRNA drugs to non-liver tissues remains the field's greatest challenge. Approaches under investigation include peptide-conjugated siRNAs for muscle delivery, intrathecal administration for central nervous system diseases, and ocular delivery for retinal disorders. ## Advantages and Limitations of siRNA Drugs Understanding the strengths and weaknesses of siRNA drugs relative to other therapeutic modalities is essential for evaluating their place in the pharmacopeia. ### Advantages: specificity and potency The primary advantage of siRNA drugs is their extraordinary specificity. A well-designed siRNA can discriminate between target mRNAs that differ by a single nucleotide, allowing selective silencing of mutant alleles while preserving wild-type function. This is particularly valuable for dominant genetic disorders where the mutant allele must be silenced without affecting the normal copy. Potency is another major advantage. Because each RISC complex is catalytic, a single siRNA molecule can cleave multiple mRNA transcripts. This catalytic amplification means that very low intracellular concentrations of siRNA (picomolar range) are sufficient for effective gene silencing. The duration of effect is also prolonged—weeks to months—which enables infrequent dosing. siRNA drugs can target any gene with a known mRNA sequence, including genes that encode proteins that are difficult to inhibit with small molecules. [Transcription factors](/knowledge/molecular-biology/transcription-factor), scaffolding proteins, and long non-coding RNAs are all amenable to siRNA-mediated silencing. This "sequence-based druggability" is fundamentally different from the structure-based druggability of small molecules. ### Limitations: stability, delivery, off-target effects The most significant limitation of siRNA drugs is delivery. The liver is the only organ that can be efficiently targeted with current technology, and even hepatic delivery requires specialized formulations. Non-liver tissues—muscle, adipose, brain, lung—remain largely inaccessible to systemically administered siRNA drugs. Stability is a related concern. Despite chemical modifications, siRNA drugs are degraded by nucleases and cleared by renal filtration. The half-life of GalNAc-conjugated siRNAs in circulation is on the order of hours, though the intracellular residence time is much longer. For LNP-formulated siRNAs, the drug must be administered intravenously, which is inconvenient for chronic diseases. Off-target effects remain a concern. The seed region of the guide strand (nucleotides 2–8) can base-pair with unintended mRNAs with partial complementarity, leading to translational repression or mRNA destabilization of off-target genes. Additionally, certain RNA sequence motifs can stimulate the innate immune system via Toll-like receptors (TLR3, TLR7, TLR8) or cytoplasmic sensors such as RIG-I. Chemical modifications reduce but do not eliminate these effects. Finally, the cost of siRNA drugs is substantial. The approved drugs are priced in the hundreds of thousands of dollars per year, reflecting the high development costs and the small patient populations for rare diseases. Whether siRNA drugs can be cost-effective for common diseases like hypercholesterolemia remains an open question. ## Methods Used to Study siRNA Drugs The development of siRNA drugs relies on a suite of experimental techniques spanning molecular biology, cell biology, and pharmacology. ### In vitro screening Initial evaluation of siRNA candidates begins in cell culture. The standard workflow involves: 1. **Cell culture**: Target cells (typically hepatocyte cell lines such as HepG2 or Huh7 for liver-targeting siRNAs) are cultured in appropriate media, usually DMEM or RPMI supplemented with 10% fetal bovine serum and antibiotics, at 37°C in 5% CO₂. 2. **Transfection**: siRNAs are introduced into cells using lipid-based transfection reagents at concentrations typically ranging from 1–100 nM. The transfection efficiency is monitored using fluorescently labeled siRNAs or a positive control siRNA targeting a housekeeping gene. 3. **Gene expression analysis**: Silencing efficiency is quantified by measuring target mRNA levels using quantitative [reverse transcription PCR](/knowledge/diagnostics/molecular/reverse-transcription-pcr-principles-protocol-cdna-synthesis) (qRT-PCR) 24–48 hours post-transfection. Protein levels are assessed by Western blot or ELISA 48–72 hours post-transfection. 4. **Dose-response analysis**: Serial dilutions of the siRNA are tested to determine the half-maximal inhibitory concentration (IC₅₀), which typically ranges from 0.1–10 nM for potent siRNAs. 5. **Off-target assessment**: Genome-wide expression profiling by RNA sequencing can identify unintended gene expression changes, while phenotypic assays evaluate cellular viability and proliferation. For a detailed protocol on siRNA delivery in cultured cells, see the article on [siRNA transfection](/knowledge/molecular-biology/sirna-transfection). ### In vivo efficacy studies Promising siRNA candidates are evaluated in animal models before clinical development. The standard approach involves: - **Mouse models**: Wild-type mice or disease models (transgenic, knockout, or chemically induced) are administered the siRNA drug by the intended clinical route (intravenous for LNP, subcutaneous for GalNAc conjugates). - **Dose-response studies**: Doses typically range from 0.3–10 mg/kg for GalNAc conjugates and 0.1–3 mg/kg for LNP formulations. The target mRNA and protein levels are measured in the liver at various time points (days to weeks) after administration. - **Duration of effect**: The duration of gene silencing is determined by serial measurements, which informs the dosing interval for clinical studies. - **Toxicology**: Standard toxicology studies evaluate body weight, clinical chemistry (liver enzymes, kidney function), hematology, and histopathology of major organs. ### Pharmacokinetics and biodistribution Understanding the pharmacokinetics of siRNA drugs is essential for dose selection and regimen design. Key parameters include: - **Plasma concentration-time profiles**: Measured by quantitative PCR or hybridization-based assays that detect the intact siRNA. GalNAc-conjugated siRNAs typically show rapid absorption (Tmax of 1–4 hours after subcutaneous injection) and biphasic elimination. - **Tissue distribution**: Radiolabeled or fluorescently labeled siRNAs are used to track biodistribution. For liver-targeted siRNAs, the majority of the dose accumulates in the liver within hours of administration. - **Metabolism**: siRNA drugs are metabolized by exonucleases and endonucleases, generating progressively shorter metabolites. The metabolic profile is characterized using mass spectrometry. - **Pharmacodynamic modeling**: Mathematical models relate drug concentration to the extent and duration of target silencing, allowing prediction of human dosing regimens from preclinical data. ## Common Pitfalls and Misconceptions Students learning about siRNA drugs frequently encounter several conceptual difficulties. Understanding these pitfalls is essential for mastering the material. ### siRNA vs. shRNA vs. miRNA A common source of confusion is the distinction between siRNA, short hairpin RNA (shRNA), and microRNA (miRNA). While all three are small RNAs that mediate gene silencing, they differ in origin, structure, and mechanism: - **siRNA**: Exogenous, synthetic double-stranded RNA of 19–21 base pairs. It has perfect complementarity to its target mRNA and mediates endonucleolytic cleavage via Ago2. siRNA drugs are synthetic siRNAs. - **shRNA**: A single RNA molecule that forms a hairpin structure. It is typically expressed from a DNA vector (plasmid or viral) and is processed by Dicer into siRNA-like molecules. shRNA is used in research for stable gene knockdown but is not used as a drug. - **miRNA**: Endogenous, genomically encoded small RNAs of ~22 nucleotides. They are processed from primary transcripts (pri-miRNA) by Drosha and Dicer. miRNAs typically have partial complementarity to their targets and mediate translational repression and mRNA destabilization rather than endonucleolytic cleavage. The distinction matters for understanding both mechanism and therapeutic application. For a more detailed comparison, see the article on [siRNA and miRNA](/knowledge/molecular-biology/sirna-and-mirna) and the discussion of [microRNA siRNA](/knowledge/molecular-biology/microrna-sirna) differences. ### Off-target effects and immune stimulation Students often assume that siRNA drugs are completely specific because they are designed to be complementary to a single mRNA. In reality, off-target effects are a significant concern. The seed region of the guide strand can bind to hundreds of unintended mRNAs with partial complementarity, leading to their downregulation. This is mechanistically similar to miRNA-mediated silencing and is difficult to predict computationally. Immune stimulation is another frequently misunderstood aspect. Unmodified RNA is a potent activator of the innate immune system. TLR3 recognizes double-stranded RNA, TLR7 and TLR8 recognize single-stranded RNA (including the guide strand), and RIG-I recognizes 5′-triphosphate RNA. These receptors trigger type I interferon responses and inflammatory cytokine production. Chemical modifications—particularly 2′-OMe and 2′-F—reduce immune recognition, but the risk is not eliminated. The clinical relevance of immune stimulation depends on the delivery vehicle, dose, and route of administration. ### Misunderstanding RISC stoichiometry Another misconception is that one siRNA molecule silences one mRNA molecule. In reality, RISC is catalytic: a single RISC complex can cleave multiple mRNA transcripts sequentially. This catalytic amplification is why siRNA drugs are so potent and why the duration of effect can be so long. The guide strand remains associated with Ago2 for days to weeks, continuously directing cleavage of complementary mRNAs. ### Confusing delivery with transfection In research settings, "transfection" refers to the introduction of nucleic acids into cells in vitro using chemical reagents (e.g., Lipofectamine) or physical methods (e.g., electroporation). In clinical settings, "delivery" refers to the formulation and administration of the drug to achieve therapeutic concentrations in target tissues. These are fundamentally different processes with different challenges. A siRNA that works beautifully in cell culture may fail in vivo due to poor biodistribution, rapid clearance, or inadequate cellular uptake. ## Summary and Future Directions ### Emerging trends in RNAi therapeutics The future of siRNA drugs lies in expanding beyond the liver. Several approaches are being explored: - **Extrahepatic delivery**: Peptide-conjugated siRNAs targeting muscle (e.g., via the transferrin receptor), central nervous system delivery via intrathecal administration, and ocular delivery via intravitreal injection are all in clinical development. - **Tissue-specific targeting**: Beyond GalNAc, other ligands are being developed to target specific cell types. These include antibodies or antibody fragments conjugated to siRNAs, aptamers, and peptides that bind cell-type-specific receptors. - **Combination therapies**: siRNA drugs can be combined with small molecule drugs, monoclonal antibodies, or other nucleic acid therapeutics to achieve synergistic effects. For example, combining a PCSK9-targeting siRNA with a statin provides additive LDL cholesterol reduction. - **Next-generation chemistries**: Novel chemical modifications, including glycol nucleic acids (GNA) and peptide nucleic acids (PNA), may further improve stability and potency. - **Expanded indications**: As delivery technology improves, siRNA drugs will target diseases beyond the liver, including neurological disorders, muscular dystrophies, and cancer. The field of RNAi therapeutics is still young, but the fundamental principle—that we can treat disease by silencing genes—has been validated. The next decade will likely see siRNA drugs become as common as monoclonal antibodies, which themselves took decades to move from laboratory curiosity to mainstream medicine. For a broader perspective on the therapeutic landscape, the article on [siRNA therapy](/knowledge/molecular-biology/sirna-therapy) provides additional context. ## Frequently Asked Questions ### What is an siRNA drug? An siRNA drug is a therapeutic agent that uses [small interfering RNA](/knowledge/molecular-biology/small-interfering-rna) to silence a specific disease-causing gene. It works by degrading the messenger RNA (mRNA) transcribed from that gene, preventing the production of the disease-associated protein. siRNA drugs are synthetic double-stranded RNA molecules, typically 19–21 base pairs long, that are chemically modified for stability and formulated for delivery to target cells. ### How do siRNA drugs work? siRNA drugs work through the RNA interference (RNAi) pathway. After delivery into the cytoplasm of target cells, the siRNA duplex is loaded into the RNA-induced silencing complex (RISC). The guide strand remains associated with the Argonaute 2 (Ago2) protein, while the passenger strand is degraded. The guide strand then base-pairs with complementary sequences in the target mRNA, and Ago2 cleaves the mRNA, leading to its degradation. This prevents translation of the mRNA into protein, effectively silencing the target gene. ### What are some examples of siRNA drugs? Six siRNA drugs have been approved by regulatory agencies: patisiran (Onpattro) for hereditary transthyretin amyloidosis, givosiran (Givlaari) for acute hepatic porphyria, lumasiran (Oxlumo) for primary hyperoxaluria type 1, inclisiran (Leqvio) for hypercholesterolemia, vutrisiran (Amvuttra) for hereditary transthyretin amyloidosis, and nedosiran (Rivfloza) for primary hyperoxaluria type 1. Many more siRNA drugs are in clinical trials for cancer, viral infections, and other genetic diseases. ### What is the mechanism of action of siRNA drugs? The mechanism of action involves several steps: (1) the siRNA drug enters the target cell and is loaded into RISC; (2) the guide strand is selected and the passenger strand is degraded; (3) the guide strand base-pairs with complementary sequences in the target mRNA; (4) Ago2 cleaves the mRNA between nucleotides 10 and 11 relative to the guide strand 5′ end; (5) the cleaved mRNA is degraded by cellular exonucleases; and (6) the RISC complex is recycled to cleave additional mRNA molecules. This catalytic mechanism provides potent and sustained gene silencing. ### Are siRNA drugs safe? siRNA drugs have demonstrated acceptable safety profiles in clinical trials and in post-marketing experience. The most common adverse effects are injection-site reactions (for subcutaneously administered drugs) and infusion-related reactions (for intravenously administered drugs). More serious but rare adverse effects include hepatotoxicity and immune stimulation. The long-term safety of siRNA drugs is still being evaluated, but the available evidence suggests that they are generally well tolerated. ### How are siRNA drugs delivered to cells? The two main delivery platforms are lipid nanoparticles (LNPs) and GalNAc conjugates. LNPs are used for intravenous administration and deliver siRNA to the liver via endocytosis. GalNAc conjugates are administered subcutaneously and target hepatocytes specifically via the asialoglycoprotein receptor. Both approaches require endosomal escape to release the siRNA into the cytoplasm, where it can engage RISC. Delivery to non-liver tissues remains a major challenge. ### What diseases are treated with siRNA drugs? Currently approved siRNA drugs treat rare genetic diseases (hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1) and hypercholesterolemia. siRNA drugs in clinical trials are being evaluated for hepatitis B, various cancers, complement-mediated diseases, alpha-1 antitrypsin deficiency, and other conditions. The expansion of siRNA drugs to additional diseases depends on the development of delivery technologies for non-liver tissues. ## Key Takeaways - siRNA drugs are synthetic double-stranded RNA molecules that harness the endogenous RNA interference pathway to silence disease-causing genes at the mRNA level. - The mechanism involves RISC loading, guide strand selection, complementary base-pairing with target mRNA, and Ago2-mediated endonucleolytic cleavage. - Chemical modifications (2′-OMe, 2′-F, phosphorothioate linkages) and delivery vehicles (LNPs, GalNAc conjugates) are essential for stability, biodistribution, and cellular uptake. - Six siRNA drugs have been approved: patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran—all targeting liver-expressed genes. - The liver is currently the only organ that can be efficiently targeted, but extrahepatic delivery is an active area of research. - siRNA drugs offer advantages in specificity and potency but face challenges in delivery, stability, off-target effects, and cost. - siRNA drugs differ from shRNA and miRNA in origin, structure, and mechanism, and these distinctions are important for understanding their therapeutic applications. ## Further Reading - Guo S, Zhang M, Huang Y. *Three 'E' challenges for siRNA drug development*. Trends in molecular medicine. 2024. [PubMed 37951790](https://doi.org/10.1016/j.molmed.2023.10.005) - Ahn I, Kang CS, Han J. *Where should siRNAs go: applicable organs for siRNA drugs*. Experimental & molecular medicine. 2023. [PubMed 37430086](https://doi.org/10.1038/s12276-023-00998-y) - Imran Sajid M et al. *siRNA drug delivery across the blood-brain barrier in Alzheimer's disease*. Advanced drug delivery reviews. 2023. [PubMed 37353152](https://doi.org/10.1016/j.addr.2023.114968) - Xiao B et al. *Development, opportunities, and challenges of siRNA nucleic acid drugs*. Molecular therapy. Nucleic acids. 2025. [PubMed 39897581](https://doi.org/10.1016/j.omtn.2024.102437) - Ngamcherdtrakul W, Yantasee W. *siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion*. [Translational research](/blog/news/translational-research) : the journal of laboratory and clinical medicine. 2019. [PubMed 31487500](https://doi.org/10.1016/j.trsl.2019.08.005) - Liu H et al. *SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment*. Biomaterials. 2014. [PubMed 24797882](https://doi.org/10.1016/j.biomaterials.2014.04.033)
## Related Clinical & Scientific Guides * [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway) * [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor) * [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)